Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Blood (2023) 142 (Supplement 1): 843.

https://doi.org/10.1182/blood-2023-187315

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Sonja Bendig, Sandra Bufe, Birgit Fricke, Constantin Proske, Nikos Darzentas, Britta Kehden, Guranda Chitadze, Claudia D Baldus, Michaela Kotrova, Nicola Goekbuget, Monika Brüggemann

Blood (2023) 142 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2023-174458

Published: 2023

Journal Articles

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Kumaran Nagarajan, Britta Steer, Philipp Nakov, Björn Steffen, Dorothee Deckbar, Sonja Bendig, Lorenz Bastian, Martin Neumann, Monika Brueggemann, Nicola Goekbuget, Claudia D Baldus

Blood (2023) 142 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2023-173937

Published: 2023

Journal Articles

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Blood (2022) 140 (Supplement 1): 121–123.

https://doi.org/10.1182/blood-2022-158934

Published: 2022

Journal Articles

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour, Ibrahim Aldoss, Shaun Fleming, Ashish Bajel, Paul Cannell, Monika Brüggemann, Gerhard Zugmaier, Joan Morris, Yuqi Chen, Sonny Powar, Hansen Wong, Björn Steffen, Hagop Kantarjian, Nicola Goekbuget

Blood (2022) 140 (Supplement 1): 6134–6136.

https://doi.org/10.1182/blood-2022-156080

Published: 2022

Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Blood (2022) 140 (Supplement 1): 510–512.

https://doi.org/10.1182/blood-2022-162235

Published: 2022

Journal Articles

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Blood (2022) 140 (Supplement 1): 1053–1055.

https://doi.org/10.1182/blood-2022-163311

Published: 2022

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Monika Szczepanowski, Johanna Richter, Miriam Kelm, Heiko Trautmann, Britta Kehden, Matthias Ritgen, Christoph Faul, Kathrin Nachtkamp, Björn Steffen, Andreas Viardot, Johannes Gärtner, Johannes Duell, Claudia D. Baldus, Stefan Schwartz, Nicola Goekbuget, Monika Brüggemann

Blood (2021) 138 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2021-150375

Published: 2021

Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Blood (2021) 138 (Supplement 1): 2300.

https://doi.org/10.1182/blood-2021-145553

Published: 2021

Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood (2021) 138 (Supplement 1): 362.

https://doi.org/10.1182/blood-2021-146306

Published: 2021

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Nicola Goekbuget, Andrea Stoltefuß, Max Topp, Stefan Schwartz, Andrea Renzelmann, Christoph Faul, Bernd Hertenstein, Vladan Vucinic, Maria Wachsmuth, Anne C Wilke, Lena Baumann, Diana Tichy, Monika Brüggemann, Andreas Viardot

Blood (2021) 138 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2021-146214

Published: 2021

Journal Articles

Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-141921

Published: 2020

Journal Articles

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, MD, Simon Raffel, MD, Ralph Wäsch, Sebastian Scholl, Mustafa Kondakci, MD, Andreas Rank, PD Dr, Mathias Haenel, MD, Sonja Martin, MD, Katjana Schwab, MD, Julian Knaden, Klaus Wethmar, MD, Tim Sauer, MD, Wolfgang E. Berdel, Prof., MD, Georg Lenz, Martin Dugas, Monika Brüggemann, MD, Nicola Goekbuget, MD, Nael Alakel, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-136920

Published: 2020

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Lorenz Bastian, Sonja Hänzelmann, Martin Neumann, Alina Hartmann, Thomas Burmeister, Stefan Schwartz, Walter Fiedler, MD, Mustafa Kondakci, MD, Andreas Viardot, Professor Dr, Folker Schneller, Christoph Faul, MD, Max S. Topp, MD, Sören Franzenburg, Andre Franke, Heiko Trautmann, PhD, Nicola Goekbuget, MD, Monika Brüggemann, MD, Claudia D Baldus, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143032

Published: 2020

Journal Articles

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Michaela Kotrova, MD PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2018-99-112844

Published: 2018

Journal Articles

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Blood (2018) 132 (Supplement 1): 660.

https://doi.org/10.1182/blood-2018-99-111954

Published: 2018

NARROW

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Reshaping MRD Detection Strategies: Next-Generation Sequencing and High DNA Input Identify Previously Missed Measurable Residual Disease in Peripheral Blood of B-Cell Precursor Acute Lmyphoblastic Leukemia

Venetoclax and Blinatumomab for Adult Patients with Relapsed/Refractory or MRD Positive Ph-Negative B-Precursor ALL: First Results of the GMALL-Bliven Trial

Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only